Publications Johan Rönnelid

Publications in DiVA

Publications in PubMed

Publication list for the years 2006-2013

Selected publications:

  1. Elbagir S, Diaz-Gallo LM, Grosso G, Zickert A, Gunnarsson I, Mahler M, Svenungsson E, Rönnelid J. Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE. Rheumatology (Oxford). 2022 Jun 1:keac327. Online ahead of print
  2. Elbagir S, Elbagir S, Sohrabian A, Elshafie AI, Elagib EM, Mohammed NA, Nur MAM, Svenungsson E, Gunnarsson I, Rönnelid J. Accumulation of anti-nuclear associated antibodies in circulating immune complexes is more prominent in SLE patients from Sudan than Sweden. Sci Rep. 2020, 10:21126.
  3. Fox B, Hockley J, Rigsby P, Dolman C, Meroni PL, Rönnelid J. A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation. Anna Rheum Dis. 2019, 78(12):1677-1680.
  4. Sohrabian A, Parodis I, Carlströmer-Berthén N, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I, Rönnelid J. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Res Ther. 2019, 21(1):259.
  5. Sohrabian A, Mathsson-Alm L, Hansson M, Knight A, Lysholm J, Cornillet M, Skriner K, Serre G, Larsson A, Weitoft T, Rönnelid J. Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis. Ann Rheum Dis. 2018, 77(9):1345-1353.
  6. Rönnelid J, Hansson M, Mathsson-Alm L, Cornillet M, Reed E, Jakobsson PJ, Holmdahl R, Skriner K, Serre G, Lundberg K, Klareskog L. Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants. Ann Rheum Dis. 2018, 77(2):203-211.
  7. Manivel VA, Mullazehi M, Padyukov L, Westerlind H, Klareskog L, Alfredsson L, Saevarsdottir S, Rönnelid J. Anti-collagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during five years follow-up. Ann Rheum Dis. 2017, 76(9):1529-1536.
  8. Hansson M, Mathsson L, Schlederer T, Israelsson L, Matsson P, Nogueira L, Jakobsson PJ, Lundberg K, Malmström V, Serre G, Holmdahl R, Nystrand R, Klareskog L, Rönnelid J. Validation of a multiplex chip-based for the detection of autoantibodies against citrullinated peptides. Athritis Res Ther. 2012, 14:R201
  9. Mullazehi M, Mathsson L, Lampa J, Rönnelid J. High anti-collagen type II antibody levels and induction of pro-inflammatory cytokines by anti-collagen antibody containing immune complexes in vitro characterize a distinct RA phenotype associated with acute inflammation at the time of disease onset. Ann Rheum Dis. 2007, 66:537-41.
  10. Mullazehi M, Mathsson L, Lampa J, Rönnelid J. Surface-bound immune complexes containing antibodies to collagen type II induce production of TNF-a, IL-1b and IL-8 from peripheral blood mononuclear cells. A potential pathophysiological mechanism for anti-collagen immunity in RA. Arthritis Rheum. 2006, 54(6):1759-71.


Last modified: 2023-01-30